Immunoglobulin News and Research

RSS

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Researchers from Cuba, China, and France have demonstrated the potential of coupling a viral antigen with the tetanus toxoid protein as a vaccination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

14 Feb 2021

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Researchers at the NYU Grossman School of Medicine have shown that a second dose of the Pfizer-BioNTech BNT162b2 vaccine may not offer any additional protection against coronavirus disease 2019 (COVID-19) over one dose among individuals previously infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Feb 2021

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.

10 Feb 2021

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Researchers at Northwestern University have noted high rates of asymptomatic and mild infection in a large community-based cohort and low levels of anti-SARS-CoV-2 immunoglobulin G antibody (IgG) in the general population of previously exposed people.

10 Feb 2021

Pediatric trial results show rabies treatment is safe and effective in children

A treatment, known as KEDRAB (Rabies Immune Globulin [Human]), currently used in the prevention of rabies has been demonstrated to be safe and effective for patients age 17 and under.

10 Feb 2021

Study reveals new molecular mechanism linked to severe anaphylaxis

Anaphylaxis is a systemic allergic reaction that can affect the skin, the gastrointestinal tract, the respiratory system and the cardiovascular system.

9 Feb 2021

Smell and taste loss symptoms associated with robust SARS-CoV-2 antibody response in new study

Researchers in Italy report a correlation between the loss of smell and taste and an observed persistence or rise in antibody levels at five months after infection.

9 Feb 2021

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

A new study describes the first case of anti-SARS-CoV-2 antibodies detected in the cord blood of an infant born to a mother immunized with the first dose of an mRNA COVID-19 vaccine three weeks earlier.

9 Feb 2021

Orthodox Jewish in UK disproportionately impacted by COVID-19

Researchers have conducted a study showing an extremely high prevalence of severe acute respiratory coronavirus disease 2 (SARS-CoV-2) within a strictly Orthodox Jewish community in the UK.

7 Feb 2021

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

A new preprint research paper posted to the bioRxiv server reports the development of highly effective neutralizing nanobodies targeting the viral receptor-binding domain (RBD), thus disrupting its engagement with the host cell angiotensin-converting enzyme 2 (ACE2) receptor.

4 Feb 2021

SHREK proteins mediate broad spectrum antiviral host immunity, including against SARS-CoV-2

A new preprint posted to the bioRxiv server demonstrates that similar mucins and mucin-like proteins cannot only suppress HIV-1 infectivity via blockage of viral attachment to the host cells but can block infection by multiple enveloped viruses.

4 Feb 2021

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Among these is the B.1.1.7 SARS-CoV-2 variant, with its characteristic N501Y mutation. A new preprint on the bioRxiv server reports the impact of this mutation on CD4 T cell responses, including antigen presentation on cells expressing Major Histocompatibility Complex (MHC) class II molecules.

4 Feb 2021

Researchers develop rapid COVID-19 diagnostic test affordable for low-income families

A test that detects antibodies to the novel coronavirus in 10 minutes and costs only a fifth of the market average has been developed by researchers at the University of São Paulo's São Carlos Chemistry Institute and Brazilian startup Biolinker, with São Paulo Research Foundation - FAPESP's support.

2 Feb 2021

Previous SARS-CoV-2 infection may negate need for two vaccine doses

Researchers in the United States have shown that two doses of vaccine may not be necessary to protect against coronavirus disease 2019 (COVID-19) among people who have already been infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Feb 2021

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

In the absence of effective therapeutics or preventives, vaccines have become the focus of attention. Though over 170 vaccines are in preclinical and about 60 in clinical development, very few are based on plasmid DNA technology. However, a new preprint research paper posted to the bioRxiv* server reports the immunogenicity of a DNA vaccine candidate.

2 Feb 2021

New platform for detecting and monitoring SARS-CoV-2 antibody responses

Researchers in the U.S. have released a new study that describes a powerful but inexpensive tool designed to detect and monitor specific antibodies to SARS-CoV-2 over time.

1 Feb 2021

Fetal and neonatal therapy combination may lessen the aftereffects of congenital CMV infection

A cross-institutional research group has revealed for the first time in the world that infants with symptomatic congenital cytomegalovirus (CMV) infection who were treated with a combination of immunoglobulin fetal therapy and neonatal therapy with antiviral drugs were less likely to experience the severe aftereffects associated with the infection than those who only received the neonatal therapy.

28 Jan 2021

Moderna vaccine shows robust suppression of SARS-CoV-2 infection in animal model

Researchers have demonstrated that the prime or prime-boost vaccination of Moderna vaccine in hamsters induced robust neutralizing antibodies, ameliorated weight loss, and suppressed SARS-CoV-2 replication in the airways.

28 Jan 2021

What do we know about the SARS-CoV-2 vaccines so far?

A new study surveys what we know so far about SARS-CoV-2 vaccine candidates from advanced clinical trials.

27 Jan 2021

Antibodies and inflammatory markers may help identify COVID-19 cases and predict severity

A new preprint appearing on the medRxiv server describes the changes that occur in numerous antibodies and inflammatory molecules with age and at varying stages, or severity, of the infection and resulting illness. The results may help to predict the risk in individual cases.

26 Jan 2021

Immunoglobulin News and Research

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Pediatric trial results show rabies treatment is safe and effective in children

Study reveals new molecular mechanism linked to severe anaphylaxis

Smell and taste loss symptoms associated with robust SARS-CoV-2 antibody response in new study

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

Orthodox Jewish in UK disproportionately impacted by COVID-19

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

SHREK proteins mediate broad spectrum antiviral host immunity, including against SARS-CoV-2

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Researchers develop rapid COVID-19 diagnostic test affordable for low-income families

Previous SARS-CoV-2 infection may negate need for two vaccine doses

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

New platform for detecting and monitoring SARS-CoV-2 antibody responses

Fetal and neonatal therapy combination may lessen the aftereffects of congenital CMV infection

Moderna vaccine shows robust suppression of SARS-CoV-2 infection in animal model

What do we know about the SARS-CoV-2 vaccines so far?

Antibodies and inflammatory markers may help identify COVID-19 cases and predict severity

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News